Pacira Jumps After Settling US Patent Litigation for Exparel (2)

(Updates share move; adds analyst commentary.)

Pacira BioSciences shares soar as much as 21%, the most intraday in seven years, after the company said it had settled litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals and eVenus Pharmaceuticals Laboratories related to patents for Exparel.

• Pacira agreed to license Fresenius to its patents to manufacture and sell volume-limited amounts of generic bupivacaine liposome injectable suspension in US in early 2030
• Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in US without volume limitations beginning in 2039

ANALYST COMMENTARY

Raymond James (market perform)

• Analyst Gary Nachman says the settlement appears ...